Browsing Tag
docetaxel
2 posts
JNJ’s pasritamig plus docetaxel advances to Phase 3 after strong early results in metastatic castration-resistant prostate cancer
Johnson & Johnson's pasritamig hits 75% PSA response in taxane-naive prostate cancer patients. What Phase 3 means for JNJ's oncology strategy. Read more.
Game-changer for prostate cancer: Veracyte’s test predicts who will benefit from chemo
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced compelling new data from the phase 3…